Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
October 26, 2017 10:23 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
April 24, 2017 10:28 ET
|
Vaccinex, Inc.
- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
October 06, 2016 09:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to evaluate VX15/2503, an...
Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial
September 09, 2016 09:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
August 23, 2016 10:15 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
August 01, 2016 10:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...
Vaccinex Announces Publication of Results From a Phase I Trial of Anti-Semaphorin 4D Antibody, VX15/2503, in Patients With Advanced Solid Tumors
October 20, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer...
Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington's Disease (the SIGNAL Trial)
June 24, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 24, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D...
Vaccinex Provides an Update on Its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients
March 31, 2015 13:17 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 31, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced the successful completion of a multicenter phase 1, randomized, double-blind, placebo-controlled, single...
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
March 19, 2015 13:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 19, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to...